Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?

ABSTRACT: Chimeric antigen receptor (CAR) T cell immunotherapy has changed the landscape of B cell hematological malignancies' management, while it has recently shown promising results in the treatment of refractory autoimmune rheumatic disorders (ARDs). Targeting B cell antigens such as CD19 and BCMA, CAR-T cell therapy can induce sustained remission by the elimination of autoreactive B cell populations resistant to the standard of care treatment options. Clinical data from case reports and small case series demonstrate profound clinical responses in ARDs, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), and primary Sjögren's syndrome (pSS). Treatment outcomes include reduce

SUBMITTER: Anyfanti P 

PROVIDER: S-EPMC12384554 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature